21:23 , Jul 25, 2019 |  BC Innovations  |  Distillery Therapeutics

Innate Pharma's trifunctional NK cell engagers for multiple cancers

DISEASE CATEGORY: Cancer INDICATION: Lung cancer; lymphoma; solid tumors Innate Pharma S.A. showed that its trifunctional NK cell engager platform could be deployed against lymphoma, lung cancer and solid tumors. The trifunctional NK cell engagers...
01:36 , Jun 8, 2018 |  BC Innovations  |  Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...
19:11 , Feb 21, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest activating or overexpressing NCR2 could help treat melanoma. In a human melanoma cell line, supernatant from NK cells activated by the NCR2 ligand PDGFDD decreased growth compared...
18:04 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Thrombocytopenia Mouse studies suggest depleting NK cells or inhibiting NK cell activation could help treat fetal/neonatal alloimmune thrombocytopenia (FNAIT). In a mouse model of FNAIT, a tool antibody that depletes NK cells decreased uterine...
22:24 , Aug 11, 2017 |  BC Extra  |  Preclinical News

Study links FNAIT miscarriages to NK cells

In a paper published in Nature Communications , a team including scientists from St. Michael's Hospital and University of Toronto showed that NK cell activation leads to placental dysfunction and miscarriages in fetal/neonatal alloimmune thrombocytopenia...
19:45 , Jun 12, 2017 |  BC Extra  |  Company News

Celgene gets options to Dragonfly's NK receptor antibodies

Dragonfly Therapeutics Inc. (Cambridge, Mass.) and Celgene Corp. (NASDAQ:CELG) began a five-year collaboration to discover, develop and commercialize candidates to treat hematologic malignancies based on Dragonfly’s TriNKET (Trispecific NK cell Engager Therapies) platform. Celgene will...
21:59 , Mar 3, 2017 |  BioCentury  |  Emerging Company Profile

Dragonfly’s trinkets

Dragonfly Therapeutics Inc. is developing trispecific antibodies that direct endogenous NK cells toward tumor cells. By targeting two distinct activating receptors on NK cells, plus a tumor antigen, the antibodies could be more potent than...
23:02 , Nov 17, 2016 |  BC Innovations  |  Product R&D

Hemorrhaging targets

An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new...
07:00 , Jul 28, 2016 |  BC Innovations  |  Tools & Techniques

Innate harmony

On the heels of cancer immunotherapy's clinical success, NK cells - a long-known but underappreciated component of the innate immune system - are emerging as the hottest new tool to fight cancer, with the potential...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Company News

Innate Pharma, Sanofi deal

Innate and Sanofi partnered to develop and commercialize up to two bispecific natural killer (NK) engagers using Sanofi’s bispecific antibody technology and Innate’s technology targeting natural cytotoxicity triggering receptor 1 ( NCR1 ; NKP46 ;...